Research Article

Quantitative ELISA-Like Immunohistochemistry of Fibroblast Growth Factor 23 in Diagnosis of Tumor-Induced Osteomalacia and Clinical Characteristics of the Disease

Table 2

Laboratory findings of the included 14 TIO cases.

PatientSerum phosphate (mmol/L, reference 0.89–1.60)Serum ALP (U/L, reference 0–130)Serum calcium (mmol/L, reference 2.25–2.75)Serum intact PTH (pmol/L, reference 1.60–6.90)Urine phosphate (mmol/24 h)Urine calcium (mmol/L, reference 2.5–7.5)TmP/GFR (mmol/L, reference 0.80 to 1.35)FGF23 expression (absorbance at 450 nm)FGF23 RT-PCR

Case 0.34 ± 0.03687.4 ± 54.02.35 ± 0.0225.07 13.22.520.29 2.19 ± 0.31Positive
Case 0.53 ± 0.18231.1 ± 26.92.17 ± 0.057.55 15.51.170.45 0.68 ± 0.08Poor mRNA quality
Case 0.5165.4 ± 1.32.18 ± 0.116.70 30.51.600.36 1.97 ± 0.13Poor mRNA quality
Case 0.38 ± 0.06199.7 ± 4.42.30 ± 0.134.32 8.51.360.31 0.76 ± 0.09Positive
Case 0.67 ± 0.03471.0 ± 19.52.324.39 27.31.190.57 0.58 ± 0.03Poor mRNA quality
Case 0.60 ± 0.09162.8 ± 34.02.28 ± 0.097.48 21.61.200.56 1.02 ± 0.11Positive
Case 0.61 ± 0.08374.9 ± 21.52.11 ± 0.063.62 5.40.600.58 1.34 ± 0.1Positive
Case 0.59 ± 0.10323.2 ± 50.02.31 ± 0.095.38 26.47.280.58 0.93 ± 0.13Positive
Case 0.45 ± 0.03351 ± 12.72.14 ± 0.087.10 35.01.170.31 0.68 ± 0.12Positive
Case 0.52 ± 0.10333.2 ± 35.22.26 ± 0.039.42 15.62.480.45 0.67 ± 0.09Positive
Case 0.55 ± 0.19179.7 ± 14.82.15 ± 0.134.41 19.11.850.47 0.55 ± 0.07Poor mRNA quality
Case 0.51 ± 0.05141.4 ± 25.52.30 ± 0.113.99 16.01.180.44 0.49 ± 0.09Poor mRNA quality
Case 0.5064.12.37NA13.4NA0.45 0.67 ± 0.07Positive
Case 0.49 ± 0.11131.92.20 ± 0.1814.36 20.21.000.42 0.50 ± 0.04Poor mRNA quality

ALP: alkaline phosphatase; PTH: parathyroid hormone; TmP/GFR: maximum tubular resorption of phosphorus factored for glomerular filtration rate; FGF23: Fibroblast Growth Factor 23.
FGF23 was measured by the quantitative ELISA-like immunohistochemistry from formalin-fixed and paraffin-embedded tissues.
FGF23 PT-PCR was measured using the formalin-fixed and paraffin-embedded tissues.